We have located links that may give you full text access.
Journal Article
Review
The CAPITA study of protein-conjugate pneumococcal vaccine and its implications for use in adults in developed countries.
Until 1990, Hemophilus influenzae type b (HITB) was a major cause of morbidity and mortality in toddlers and young children. A vaccine consisting of purified polyribosyl ribitol phosphate (PRP), the capsular polysaccharide (CPS) of HITB, had been shown to be ineffective as an antigen in the population at risk, and this vaccine was withdrawn from the market within a few years of its introduction. By contrast, the discovery that PRP, when covalently bound to an antigenic protein, stimulated antibody production in infants and toddlers, (1) led to the development of a vaccine that has all but eradicated HITB infection and brought about a near-disappearance of this organism in the United States.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app